gp96-Ig vaccine

The gp96-Ig vaccine is a novel cell-based immunotherapy platform that utilizes a secreted form of the heat shock protein 90 family member 1 (gp96) fused to an immunoglobulin (Ig) domain. This recombinant fusion enables the secretion of the chaperone molecule from genetically engineered cells. The key mechanism involves the ability of secreted gp96-Ig to bind and deliver antigenic peptides to antigen-presenting cells (APCs), thereby stimulating robust MHC class I-mediated cross-presentation and activating cytotoxic CD8+ T lymphocyte responses. The platform provides both adjuvanticity and antigen specificity in one molecule, making it suitable for generating systemic and tissue-specific immunity against cancer or infectious diseases. The most common delivery method uses irradiated allogeneic human embryonic kidney (HEK-293) cells transfected with plasmids encoding both the fusion protein and disease-relevant antigens. Clinical development has focused on non-small cell lung cancer (NSCLC), with additional preclinical work in malaria, HIV/SIV, Zika virus, CMV, COVID-19, and other infectious diseases[2][5][6][7][8][9].

Other names

secreted heat shock protein gp96-immunoglobulin vaccinecell-based gp96-Ig-secreting vaccineheat shock protein gp96-Ig fusion protein vaccine